P3.02c-098 An Observational Study of the Efficacy and Safety of Nivolumab in Patients with Advanced NSCLC. A Galician Lung Cancer Group

Campelo, Rosario García; Areses, Maria Carmen; Barón, Francisco; Afonso-Afonso, Francisco J.; Costa, Marinha; Fernández, Natalia; Amenedo, Margarita; Curvera, Guillermo Alonso-Jaudenes; Vázquez, M. Eugenio; Simó, Rafael; Martinez, J. Mosquera; Garcia, Jorge; Gómez, Susana; Campos, Begoña; Mata, Jesús García; Herranz, Urbano Anido; Fírvida, J. L.

doi:10.1016/j.jtho.2016.11.1894

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Immune-checkpoint inhibitors offer a new paradigm of treatment options, obtaining improved objective response rates (ORR) and overall survival (OS), with satisfactory safety profiles compared to chemotherapy. The promise of immunotherapy has held-up in real life, based on the findings of international cohort studies, [6][7][8][9][10][11][12][13] with the emergence of long-term survivors (LTSs). Randomized, phase III trial results indicated 23% 2-year OS for squamous NSCLCs 1 and 29% for nonsquamous NSCLCs 2 with nivolumab, 14 and 31% with atezolizumab.…”

Section: Introductionmentioning

confidence: 99%